Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer

Im, Seock Ah; Gennari, Alessandra; Park, Y.H.; Kim, J.H.; Zhao, Jiang; Gupta, Sudeep; Fadjari, Trinugroho Heri; Tamura, Keita; Mastura, M.Y.; Abesamis-Tiambeng, Maria Luisa T.; Lim, Elaine; Lin, Ching‐Hung; Sookprasert, Aumkhae; Parinyanitikul, Napa; Tseng, Ling Ming; Lee, Sang Cheol; Caguioa, Priscilla B.; Singh, Manoj; Naito, Yoichi; Hukom, Ronald; Smruti, B K; Wang, Shoei‐Shen; Kim, S.B.; Lee, K.-H.; Ahn, Hee Kyung; Peters, Steffie M B; Kim, T.W.; Yoshino, Takayuki; Pentheroudakis, George; Curigliano, G.; Harbeck, N.

doi:10.1016/j.esmoop.2023.101541

Cited by 19 publications

(12 citation statements)

References 135 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Both licensing and reimbursement of olaparib and talazoparib is greatly varied between Asian healthcare systems. For example, in India, talazoparib is not advertised but may be imported at the expense of the patients [62]. In Korea, it is available but not reimbursed [62].…”

Section: Asiamentioning

confidence: 99%

“…For example, in India, talazoparib is not advertised but may be imported at the expense of the patients [62]. In Korea, it is available but not reimbursed [62]. In China, Indonesia and Japan, talazoparib is not yet licensed, unlike olaparib which is currently available [62].…”

Section: Asiamentioning

confidence: 99%

“…In Korea, it is available but not reimbursed [62]. In China, Indonesia and Japan, talazoparib is not yet licensed, unlike olaparib which is currently available [62]. While olaparib is not covered by government funding in Hong Kong, a means tested 'safety net' fund exists for those who meet the financial threshold [63].…”

Section: Asiamentioning

confidence: 99%

See 2 more Smart Citations

Screening and Testing for Homologous Recombination Repair Deficiency (HRD) in Breast Cancer: an Overview of the Current Global Landscape

Daly,

Naidoo,

Alabdulrahman

et al. 2024

Curr Oncol Rep

View full text Add to dashboard Cite

Purpose of Review Homologous recombination repair deficiency (HRD) increases breast cancer susceptibility and influences both prophylactic and active management of breast cancer. This review evaluates HRD testing and the therapeutic implications of HRD in a global context. Recent Findings Ongoing research efforts have highlighted the importance of HRD beyond BRCA1/2 as a potential therapeutic target in breast cancer. However, despite the improved affordability of next-generation sequencing (NGS) and the discovery of PARP inhibitors, economic and geographical barriers in access to HRD testing and breast cancer screening do not allow all patients to benefit from the personalized treatment approach they provide. Summary Advancements in HRD testing modalities and targeted therapeutics enable tailored breast cancer management. However, inequalities in access to testing and optimized treatments are contributing to widening health disparities globally.

show abstract

Section: Asiamentioning

confidence: 99%

Section: Asiamentioning

confidence: 99%

See 1 more Smart Citation

Screening and Testing for Homologous Recombination Repair Deficiency (HRD) in Breast Cancer: an Overview of the Current Global Landscape

Daly,

Naidoo,

Alabdulrahman

et al. 2024

Curr Oncol Rep

View full text Add to dashboard Cite

show abstract

“…These gures underscore the signi cant impact of breast cancer on global health and emphasize the ongoing importance of research, prevention, and treatment efforts in addressing this prevalent and life-threatening disease [8]. The values for high-income countries in Asia, such as Japan, Singapore, South Korea, and Taiwan, have perceptibly improved in reducing this disease [9,10]. However, in Pakistan, the breast cancer ratio is increasing, most probably in younger ages [11][12][13].…”

Section: Introductionmentioning

confidence: 99%

Genetics risk assessment of PALB2 polymorphism (rs249954 and rs152451) with breast cancer susceptibility among the Pashtun population of Khyber Pakhtunkhwa, Pakistan

Gul,

Khan,

Khan

et al. 2024

Preprint

View full text Add to dashboard Cite

The partner and localizer of BRCA2 (PALB2) gene play an important role in DNA damage repair and control of many biological processes. The occurrence of specific genetic variations, known as single nucleotide polymorphisms (SNPs), in the PALB2 gene has been identified as a factor contributing to an increased susceptibility to breast cancer. The SNPs in PALB2 (rs249954 and rs152451) are identified and associated with breast cancer risk, however its role remains unknown in the Pashtun ethnic group, making it necessary to explore in this population. This case-controls study included 100 breast cancer patients and 100 healthy controls. The SNPs genotyping was performed using amplification-refractory mutation system-polymerase chain reaction (ARMS-PCR). The statistical analysis revealed a significant association between the risk allele of rs249954 and an elevated breast cancer risk (P = 0.0001), while rs152451 did not exhibit a significant association (P = 0.07). Heterozygous genotype of rs249954 was linked to increased breast cancer risk (P = 0.0001), whereas rs152451 did not show a significant association (P = 0.08). Mutant genotypes of both the SNPs correlated positively with breast cancer risk (P = 0.002, P = 0.042). Additionally, rs249954 exhibited significant association with Nodal status (P=0.01), Metastasis (P=0.01) and PR status (P=0.01). While PALB2 (rs142451) failed to exhibit significant association with any of the selected demographic and clinical parameters. In conclusion, the risk allele and both the heterozygous and homozygous genotypes of rs249954 were associated with an increased risk of breast cancer, whereas only homozygous mutant genotype of rs152451 exhibited significant association. However, further studies with larger datasets and comprehensive genomic analysis are necessary to validate these findings and explore associations with other relevant SNPs.

show abstract

“…-DXd[2,18]. Эксперты NCCN и ESMO поддерживают назначение T-DXd при гормонорефрактерном раке после исчерпанности последовательных линий эндокринотерапии с включением ингибиторов CDK4 / 6 с таргетной терапией или без нее (PARPi -при мутации BRCA; алпелисиб с фулвестрантом -при мутации PIK3CA).…”

unclassified

Trastuzumab deruxtecan in the treatment of patients with advanced breast cancer with HER2-low expression: Recent studies review

Kolyadina

2023

Opuholi ženskoj reproduktivnoj sistemy

View full text Add to dashboard Cite

The review gives the definition of HER2-low status, shows its clinical and biological role in patients with advanced breast cancer. A unique mechanism of action of trastuzumab deruxtecan and potential for its use in advanced breast cancer with HER2-low expression are described. The key results of the open multicenter phase III DESTINY-Breast04 (DB-04) trial including safety data are presented. Results on the effectiveness of the drug in patients with markers of hormone resistance first presented in 2023 and the place of trastuzumab deruxtecan in the updated ESMO 2023 algorithm of hormone-positive breast cancer treatment are considered.

show abstract

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer

Cited by 19 publications

References 135 publications

Screening and Testing for Homologous Recombination Repair Deficiency (HRD) in Breast Cancer: an Overview of the Current Global Landscape

Screening and Testing for Homologous Recombination Repair Deficiency (HRD) in Breast Cancer: an Overview of the Current Global Landscape

Genetics risk assessment of PALB2 polymorphism (rs249954 and rs152451) with breast cancer susceptibility among the Pashtun population of Khyber Pakhtunkhwa, Pakistan

Trastuzumab deruxtecan in the treatment of patients with advanced breast cancer with HER2-low expression: Recent studies review

Contact Info

Product

Resources

About